HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beiersdorf Making Strategic Moves In Natural Skin Care, China, Digital; Better Late Than Never?

Executive Summary

The German firm’s sales increased 6% over the first nine months of fiscal 2019, led by La Prairie luxury, but its mass-market business remains a strategic priority. Bigger digital investments, natural skin-care launches and a sharpened focus on Nivea development in China should help spur growth in the segment.

You may also be interested in...



Beiersdorf White-Space Investments Bear Fruit In Drive To Strong 2022 Finish

In two years, prestige products, China and digital have gone from weak points in Beiersdorf’s business to leading sources of growth. After recording 11.7% organic sales in its Consumer business for the nine-month period ending 30 September, the firm is targeting 9%-10% growth in the division for the full year.

More Big Beauty Companies Partner With Digital Tech To Guide Consumer Journey

Beiersdorf AG and dermanostic will connect German consumers with physicians for mobile app-based dermatological diagnoses and product recommendations. Meanwhile, Shiseido will be leveraging Revieve’s AI Makeup Advisor to “take control over the multi-touchpoint customer journey.”

US Demand For Eucerin Drives Beiersdorf To Spread Brand Into Sun Care, Post-Acne

Beiersdorf extends Eucerin line combining skin treatment with sun care and moves the brand into post-acne category using Thiamidol ingredient. Eucerin and Aquaphor brand sales grew 18.2% in its latest quarter.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149397

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel